

# Patrick SchÄffski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/468988/publications.pdf>

Version: 2024-02-01

200  
papers

16,427  
citations

50170

46  
h-index

17055

122  
g-index

203  
all docs

203  
docs citations

203  
times ranked

17050  
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	13.9	2,484
2	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2012, 379, 1879-1886.	6.3	1,752
3	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2013, 381, 295-302.	6.3	1,144
4	Cabozantinib in Progressive Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3639-3646.	0.8	989
5	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 415-423.	5.1	864
6	Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer's Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). <i>Journal of Clinical Oncology</i> , 2009, 27, 3126-3132.	0.8	611
7	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1629-1637.	6.3	610
8	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 51-64.	5.1	491
9	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	0.8	446
10	Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 412-419.	0.8	405
11	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 923-934.	5.1	224
12	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARCO21): an international, multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1089-1103.	5.1	214
13	Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. <i>Lancet Oncology</i> , The, 2011, 12, 1045-1052.	5.1	212
14	Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology. <i>Oncologist</i> , 2009, 14, 559-570.	1.9	210
15	Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha's Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. <i>Clinical Cancer Research</i> , 2012, 18, 4458-4464.	3.2	194
16	Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. <i>Lancet Oncology</i> , The, 2020, 21, 1423-1432.	5.1	194
17	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1266.	3.8	190
18	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2020, 21, 935-946.	5.1	186

#	ARTICLE	IF	CITATIONS
19	A precision therapy against cancers driven by <i>KIT/PDGFR</i> mutations. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	157
20	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3898-3905.	0.8	151
21	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. <i>Journal of Clinical Oncology</i> , 2017, 35, 1713-1720.	0.8	148
22	A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2012, 48, 179-186.	1.3	144
23	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer EORTC 10101 Overlock trial). <i>Lancet Respiratory Medicine</i> , 2018, 6, 431-441.	5.2	134
24	A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. <i>European Journal of Cancer</i> , 2012, 48, 3036-3044.	1.3	129
25	Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. <i>Clinical Cancer Research</i> , 2014, 20, 6105-6116.	3.2	129
26	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017, 35, 3433-3439.	0.8	126
27	Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 826-838.	3.2	118
28	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , 2017, 87, 147-163.	1.3	108
29	Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). <i>European Journal of Cancer</i> , 2010, 46, 2206-2215.	1.3	94
30	Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease. <i>Oncology Research and Treatment</i> , 2014, 37, 355-362.	0.8	88
31	Phase I/II study of the LAG-3 inhibitor iperamilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
32	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. <i>European Journal of Cancer</i> , 2021, 145, 132-142.	1.3	75
33	Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors. , 2020, 208, 107479.		74
34	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5508-5508.	0.8	73
35	A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. <i>Clinical Cancer Research</i> , 2013, 19, 620-630.	3.2	64
36	Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2017, 86, 296-304.	1.3	64

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. <i>European Journal of Cancer</i> , 2019, 109, 154-161.	1.3	64
38	A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 728-735.	2.9	64
39	Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 609-618.	3.2	63
40	Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. , 2018, 6, 93.		59
41	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3555-3564.	0.8	56
42	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	0.8	56
43	A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. <i>BJU International</i> , 2011, 108, 679-686.	1.3	54
44	High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. <i>Clinical Cancer Research</i> , 2009, 15, 4066-4076.	3.2	53
45	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , 2016, 16, 22.	1.1	52
46	Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. <i>Cancer Treatment Reviews</i> , 2018, 70, 190-198.	3.4	52
47	Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1609-1618.	0.9	50
48	Circulating MicroRNAs as Easy-to-Measure Aging Biomarkers in Older Breast Cancer Patients: Correlation with Chronological Age but Not with Fitness/Frailty Status. <i>PLoS ONE</i> , 2014, 9, e110644.	1.1	49
49	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. , 2020, 8, e001246.		49
50	The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrointestinal Stromal Tumor Xenografts Carrying Heterogeneous <i>KIT</i> Mutations. <i>Clinical Cancer Research</i> , 2011, 17, 5604-5614.	3.2	48
51	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 109.	2.2	48
52	Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. , 2019, 7, 275.		48
53	A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. <i>British Journal of Cancer</i> , 2016, 114, 889-896.	2.9	46
54	A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations. <i>Blood</i> , 2016, 128, 1073-1073.	0.6	46

#	ARTICLE	IF	CITATIONS
55	Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. <i>Clinical Cancer Research</i> , 2014, 20, 6071-6082.	3.2	45
56	Biological ageing and frailty markers in breast cancer patients. <i>Aging</i> , 2015, 7, 319-333.	1.4	45
57	Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. <i>European Journal of Cancer</i> , 2011, 47, 2256-2264.	1.3	44
58	The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1897-1908.	1.9	43
59	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. <i>Future Oncology</i> , 2020, 16, 4251-4264.	1.1	43
60	Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. <i>Acta Clinica Belgica</i> , 2018, 73, 100-109.	0.5	42
61	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 "CaboGIST". <i>European Journal of Cancer</i> , 2020, 134, 62-74.	1.3	42
62	Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. <i>Acta Oncologica</i> , 2018, 57, 498-508.	0.8	41
63	International expert opinion on patient-tailored management of soft tissue sarcomas. <i>European Journal of Cancer</i> , 2014, 50, 679-689.	1.3	40
64	Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients. <i>PLoS ONE</i> , 2012, 7, e48372.	1.1	40
65	Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. <i>JCI Insight</i> , 2016, 1, e86051.	2.3	39
66	The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. <i>Oncotarget</i> , 2016, 7, 29977-29988.	0.8	39
67	Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models. <i>Translational Oncology</i> , 2014, 7, 665-671.	1.7	38
68	Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 305-312.	1.1	37
69	SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 3718-3731.	3.2	36
70	A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours. <i>Journal of Controlled Release</i> , 2020, 325, 191-197.	4.8	36
71	Pazopanib in the treatment of soft tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 711-723.	1.1	35
72	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 "CREATE". <i>European Journal of Cancer</i> , 2018, 94, 156-167.	1.3	35

#	ARTICLE	IF	CITATIONS
73	Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma. <i>Marine Drugs</i> , 2009, 7, 57-70.	2.2	34
74	Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 505-513.	1.2	34
75	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e981-e994.	0.9	34
76	Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti-“Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e205-e214.	0.9	33
77	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. <i>British Journal of Cancer</i> , 2019, 120, 1026-1032.	2.9	33
78	Biology and management of clear cell sarcoma: state of the art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 839-845.	1.1	31
79	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. <i>Acta Oncologica</i> , 2014, 53, 1413-1422.	0.8	30
80	Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different <i>KIT</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2845-2852.	1.9	30
81	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021, 26, e639-e649.	1.9	29
82	Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 239-249.	1.5	28
83	Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. <i>Future Oncology</i> , 2007, 3, 381-392.	1.1	27
84	Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2014, 27, 1510-1520.	2.9	27
85	Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. <i>European Journal of Cancer</i> , 2021, 156, 12-23.	1.3	26
86	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes. <i>Journal of Clinical Oncology</i> , 2013, 31, 10503-10503.	0.8	26
87	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFR</i> Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , 2021, 27, 6333-6342.	3.2	25
88	Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. <i>Journal of Clinical Oncology</i> , 2015, 33, 6012-6012.	0.8	25
89	Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. <i>Clinical Sarcoma Research</i> , 2014, 4, 10.	2.3	24
90	Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients. <i>Acta Clinica Belgica</i> , 2016, 71, 383-388.	0.5	24

#	ARTICLE	IF	CITATIONS
91	Validation of <i>VEGFR1</i> rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib. <i>BJU International</i> , 2016, 118, 890-901.	1.3	23
92	Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1168-1178.	1.9	23
93	Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis. <i>Sarcoma</i> , 2020, 2020, 1-9.	0.7	23
94	BOS172738, a highly potent and selective RET inhibitor, for the treatment of <i>RET</i> -altered tumors including <i>RET</i> -fusion+ NSCLC and <i>RET</i> -mutant MTC: Phase 1 study results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3008-3008.	0.8	23
95	Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. <i>European Journal of Cancer</i> , 2017, 75, 33-40.	1.3	22
96	The footprint of the ageing stroma in older patients with breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 78.	2.2	22
97	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA10502-LBA10502.	0.8	22
98	The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. <i>European Journal of Cancer</i> , 2014, 50, 972-980.	1.3	20
99	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. <i>BMC Cancer</i> , 2019, 19, 794.	1.1	20
100	Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2021, 26, e622-e631.	1.9	20
101	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb004) in metastatic soft-tissue sarcomas. <i>Cancer</i> , 2019, 125, 2445-2454.	2.0	19
102	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the <i>INVICTUS</i> Study. <i>Oncologist</i> , 2021, 26, e2053-e2060.	1.9	19
103	Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or <i>RET</i> mutations: Results from a phase III study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6000-6000.	0.8	19
104	New targets and therapies for gastrointestinal stromal tumors. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1117-1129.	1.1	18
105	Mismatch repair deficiency is rare in bone and soft tissue tumors. <i>Histopathology</i> , 2021, 79, 509-520.	1.6	18
106	Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 330-330.	0.8	17
107	Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. <i>Acta Oncologica</i> , 2022, 61, 22-29.	0.8	17
108	Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11011-11011.	0.8	16

#	ARTICLE	IF	CITATIONS
109	Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. <i>Clinical Cancer Research</i> , 2014, 20, 5663-5671.	3.2	15
110	<i>In Vivo</i> Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1566-1575.	1.9	15
111	A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 "CREATE"™ trial. <i>European Journal of Cancer</i> , 2019, 109, 192-195.	1.3	15
112	Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2504-2504.	0.8	15
113	Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models. <i>Translational Oncology</i> , 2015, 8, 112-118.	1.7	14
114	Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach. <i>Oncology Research and Treatment</i> , 2016, 39, 811-816.	0.8	14
115	First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours. <i>European Journal of Cancer</i> , 2017, 86, 240-247.	1.3	14
116	Anagrelide for Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 1676-1687.	3.2	14
117	Cabozantinib as an emerging treatment for sarcoma. <i>Current Opinion in Oncology</i> , 2020, 32, 321-331.	1.1	14
118	Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. , 2021, 9, e002998.		14
119	Retrospective Analysis of Outcome of Patients with Metastatic Leiomyosarcoma in a Tertiary Referral Center. <i>Oncology Research and Treatment</i> , 2018, 41, 206-213.	0.8	13
120	PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. <i>Clinical and Experimental Medicine</i> , 2019, 19, 201-210.	1.9	13
121	First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours. <i>European Journal of Cancer</i> , 2022, 169, 135-145.	1.3	13
122	Administration of 24-h Intravenous Infusions of Trabectedin in Ambulatory Patients with Mesenchymal Tumors via Disposable Elastomeric Pumps: An Effective and Patient-Friendly Palliative Treatment Option. <i>Onkologie</i> , 2012, 35, 14-17.	1.1	12
123	A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 99-108.	1.1	12
124	Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib. <i>Clinical Cancer Research</i> , 2021, 27, 6737-6748.	3.2	12
125	A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. <i>Oncology Research and Treatment</i> , 2021, 44, 547-556.	0.8	11
126	Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11506-11506.	0.8	11



#	ARTICLE	IF	CITATIONS
127	Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center. <i>Oncology Research and Treatment</i> , 2019, 42, 396-404.	0.8	10
128	Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA". <i>European Journal of Cancer</i> , 2021, 152, 26-40.	1.3	10
129	Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs. <i>Cancers</i> , 2019, 11, 882.	1.7	9
130	Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors. <i>Translational Oncology</i> , 2020, 13, 100832.	1.7	9
131	Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST. <i>Journal of Clinical Oncology</i> , 2019, 37, 11006-11006.	0.8	9
132	Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial. <i>Cancers</i> , 2021, 13, 6057.	1.7	9
133	Machine learning for rhabdomyosarcoma histopathology. <i>Modern Pathology</i> , 2022, 35, 1193-1203.	2.9	9
134	Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. <i>Acta Oncologica</i> , 2016, 55, 329-340.	0.8	8
135	Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. <i>Scientific Reports</i> , 2020, 10, 5178.	1.6	8
136	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. <i>European Journal of Cancer</i> , 2021, 154, 253-268.	1.3	8
137	A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209. <i>Journal of Clinical Oncology</i> , 2018, 36, 6021-6021.	0.8	7
138	Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts. <i>BMC Cancer</i> , 2019, 19, 724.	1.1	6
139	An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor. <i>Oncology Research and Treatment</i> , 2020, 43, 470-473.	0.8	6
140	The added value of geriatric assessment in evaluating a patient's Health-Related Quality of Life: A study in "70" year old early stage invasive breast cancer patients. <i>European Journal of Cancer Care</i> , 2020, 29, e13278.	0.7	6
141	Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 3018-3018.	0.8	6
142	A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor. <i>BMC Cancer</i> , 2022, 22, 511.	1.1	6
143	A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS). <i>Journal of Clinical Oncology</i> , 2022, 40, 3004-3004.	0.8	6
144	Retroperitoneal Dedifferentiated Liposarcomas with Production of $\beta$ -Human Chorionic Gonadotropin "a" a Distinct Sarcoma Entity?. <i>Onkologie</i> , 2011, 34, 122-125.	1.1	5

#	ARTICLE	IF	CITATIONS
145	Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 83-90.	1.1	5
146	Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies. <i>Acta Clinica Belgica</i> , 2019, 74, 169-179.	0.5	5
147	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. <i>PLoS ONE</i> , 2020, 15, e0238809.	1.1	5
148	Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2021, 27, 3106-3115.	3.2	5
149	Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11037-11037.	0.8	5
150	ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib. <i>Acta Clinica Belgica</i> , 2019, 74, 180-188.	0.5	4
151	Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e235-e246.	0.9	4
152	Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. <i>Sarcoma</i> , 2021, 2021, 1-12.	0.7	4
153	A Robust Method for Sample Preparation of Gastrointestinal Stromal Tumour for LC/MS Untargeted Metabolomics. <i>Metabolites</i> , 2021, 11, 554.	1.3	4
154	Sphincter sparing resection of a large obstructive distal rectal gastrointestinal stromal tumour after neoadjuvant therapy with imatinib (Glivec). <i>BMJ Case Reports</i> , 2015, 2015, bcr2014207775-bcr2014207775.	0.2	4
155	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10009-10009.	0.8	4
156	Efficacy of BLU-285, a novel, potent inhibitor of Exon 17 Mutant KIT and PDGFRA D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11030-11030.	0.8	4
157	PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 568-581.	1.9	4
158	In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor. <i>Biomedicines</i> , 2022, 10, 1135.	1.4	4
159	Prognostic impact of baseline serum C-reactive protein in metastatic renal cell carcinoma treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2013, 31, 425-425.	0.8	3
160	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA10502-LBA10502.	0.8	3
161	Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2022, 40, 101-101.	0.8	3
162	Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7493.	1.8	3

#	ARTICLE	IF	CITATIONS
163	The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I. <i>BMC Medical Imaging</i> , 2014, 14, 19.	1.4	2
164	Treatment options for anthracycline-resistant, advanced soft-tissue sarcoma: the role of eribulin. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 445-453.	0.5	2
165	A Case of Severe Acute Cardiac Failure on Sunitinib After Left-Sided Thoracal Radiation Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e155-e158.	0.9	2
166	Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma. <i>Sarcoma</i> , 2017, 2017, 1-7.	0.7	2
167	Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18Fâ€“FDG-PET/CT. <i>BMC Cancer</i> , 2018, 18, 253.	1.1	2
168	Regarding â€œThe Activity of Chemotherapy in Inflammatory Myofibroblastic Tumorsâ€œ. <i>Oncologist</i> , 2020, 25, e2017-e2017.	1.9	2
169	Management of Synovial Sarcoma in a Tertiary Referral Center: A Retrospective Analysis of 134 Patients. <i>Oncology Research and Treatment</i> , 2021, 44, 232-241.	0.8	2
170	Retrospective Analysis of the Clinical Presentation, Treatment and Outcome of Angiosarcoma in a Sarcoma Referral Center. <i>Oncology Research and Treatment</i> , 2021, 44, 322-332.	0.8	2
171	Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. <i>Current Oncology</i> , 2021, 28, 3227-3239.	0.9	2
172	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2173-2181.	0.5	2
173	Abstract P5-19-10: Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer. , 2015, , .		2
174	Association between body weight and efficacy outcomes during trabectedin therapy for recurrent advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10047-10047.	0.8	2
175	Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10573-10573.	0.8	2
176	Pazopanib in uterine sarcoma (Uts): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2014, 32, 10579-10579.	0.8	2
177	Importance and role of independent data monitoring committees (IDMCs) in oncology clinical trials. <i>BMJ Open</i> , 2021, 11, e047294.	0.8	2
178	Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 â€œCREATEâ€œ-Trial. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5689.	1.8	2
179	Clinical Response of Renal Cell Carcinoma to Dexamethasone. <i>Cancer Investigation</i> , 2009, 27, 529-532.	0.6	1
180	Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e407-e410.	0.9	1

#	ARTICLE	IF	CITATIONS
181	iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study. <i>Cancer Imaging</i> , 2020, 20, 79.	1.2	1
182	Curative, Organ-Sparing, Multimodal, Perioperative Treatment of a Young Patient with a Rectoanal Inflammatory Myofibroblastic Tumor. <i>Oncology Research and Treatment</i> , 2021, 44, 269-275.	0.8	1
183	Phase I safety and pharmacokinetic (PK) dose escalation study with SAR245408 (S) polymorph E, a PI3K inhibitor, in patients (pts) with solid tumors or lymphoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13599-e13599.	0.8	1
184	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11540-11540.	0.8	1
185	Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma. <i>Biomedicines</i> , 2022, 10, 862.	1.4	1
186	Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 "CaboGIST"™. <i>Acta Oncologica</i> , 2022, 61, 663-668.	0.8	1
187	Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7454.	1.8	1
188	The impact of genetic variability on severe toxicity of (neo-) adjuvant chemotherapy in breast cancer patients receiving 5-fluorouracil, epirubicin, and cyclofosfamide (FEC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1020-1020.	0.8	0
189	Efficacy of the phosphoinositol 3 kinase (PI3K) inhibitor GDC-0941 in patient- and cell-line-derived xenografts of dedifferentiated liposarcoma (DDLPS).. <i>Journal of Clinical Oncology</i> , 2013, 31, e13528-e13528.	0.8	0
190	EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS10576-TPS10576.	0.8	0
191	Single-center experience with advanced liposarcoma (LPS): Overall survival (OS), prognostic factors and chemotherapy outcome.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22521-e22521.	0.8	0
192	Single-center experience with metastatic leiomyosarcoma: Survival, prognostic factors and outcome of chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22531-e22531.	0.8	0
193	Case Report: An Unusual Course of Angiosarcoma After Lung Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 789851.	2.2	0
194	Title is missing!. , 2020, 15, e0238809.		0
195	Title is missing!. , 2020, 15, e0238809.		0
196	Title is missing!. , 2020, 15, e0238809.		0
197	Title is missing!. , 2020, 15, e0238809.		0
198	PEC-PRO: A new prognostic score from a series of 93 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11571-11571.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and the Implications of New Biomarkers. Internal Medicine, 2022, , .	0.3	0
200	A phase II/III, randomized, open-label, multicenter study of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma (DDLPS): Brightline-1.. Journal of Clinical Oncology, 2022, 40, TPS11586-TPS11586.	0.8	0